Search

Your search keyword '"Beelen D"' showing total 983 results
Start Over Author "Beelen D"
983 results on '"Beelen D"'

1. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Author

Domingo-Domenech, E., Duarte, R. F., Boumedil, A., Onida, F., Gabriel, I., Finel, H., Arcese, W., Browne, P., Beelen, D., Kobbe, G., Veelken, H., Arranz, R., Greinix, H., Lenhoff, S., Poiré, X., Ribera, J. M., Thompson, J., Zuckerman, T., Mufti, G. J., Cortelezzi, A., Olavarria, E., Dreger, P., Sureda, A., and Montoto, S.

Published
2021
Full Text
View/download PDF

2. AFT Dating of Clinker on Black Mesa, Navajo Nation Fieldwork on the Navajo Nation was conducted under a permit from the Navajo Nation Minerals Department. Any person(s) wishing to conduct geologic investigations on the Navajo Nation must first apply for and receive a permit from the Navajo Nation

Author

Donelick, Raymond, primary, Craig, Benjamin T, additional, Begay, J, additional, Klein, B, additional, Beelen, D, additional, Foster, D A, additional, Donelick, R, additional, and Webster, Kevin D, additional

Published
2023
Full Text
View/download PDF

3. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes

Author

Martino, R, Henseler, A, van Lint, M, Schaap, N, Finke, J, Beelen, D, Vigouroux, S, Alessandrino, E P, Mufti, G J, Veelken, J H, Bruno, B, Yakoub-Agha, I, Volin, L, Maertens, J, Or, R, Leblond, V, Rovira, M, Kalhs, P, Alvarez, A F, Vitek, A, Sierra, J, Wagner, E, Robin, M, de Witte, T, and Kröger, N

Published
2017
Full Text
View/download PDF

5. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

Author

van Gelder, M, de Wreede, L C, Bornhäuser, M, Niederwieser, D, Karas, M, Anderson, N S, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J J, Yakoub-Agha, I, Russell, N H, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispízua, Á, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, van Biezen, A, Henseler, A, Schönland, S, Kröger, N, and Schetelig, J

Published
2017
Full Text
View/download PDF

6. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

Author

Robin, M, Porcher, R, Zinke-Cerwenka, W, van Biezen, A, Volin, L, Mufti, G, Craddock, C, Finke, J, Richard, C, Passweg, J, Peniket, A, Maertens, J, Sucak, G, Gedde-Dahl, T, Vitek, A, Nagler, A, Blaise, D, Beelen, D, Maillard, N, Schwerdtfeger, R, de Witte, T, and Kroger, N

Published
2017
Full Text
View/download PDF

11. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

Author

Krug, U, Berdel, W E, Gale, R P, Haferlach, C, Schnittger, S, Müller-Tidow, C, Braess, J, Spiekermann, K, Staib, P, Beelen, D, Serve, H, Schliemann, C, Stelljes, M, Balleisen, L, Maschmeyer, G, Grüneisen, A, Eimermacher, H, Giagounidis, A, Rasche, H, Hehlmann, R, Lengfelder, E, Thiel, E, Reichle, A, Aul, C, Ludwig, W-D, Kern, W, Haferlach, T, Köpcke, W, Görlich, D, Sauerland, M C, Heinecke, A, Wörmann, B J, Hiddemann, W, and Büchner, T

Published
2016
Full Text
View/download PDF

15. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)

Author

Kröger, N, Bornhäuser, M, Stelljes, M, Pichlmeier, U, Trenschel, R, Schmid, C, Arnold, R, Martin, H, Heinzelmann, M, Wolschke, C, Meyer, R G, Bethge, W, Kobbe, G, Ayuk, F, Gökbuget, N, Hölzer, D, Zander, A, and Beelen, D

Published
2015
Full Text
View/download PDF

17. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT

Author

Forcade, E., Chevret, S., Finke, J., Ehninger, G., Ayuk, F., Beelen, D., Koster, L, Ganser, A., Volin, L., Sengeloev, H., Michallet, M., Tischer, J., Jindra, P., Cascon, M.J.P., Koc, Y., Arat, M., Tomaszewska, A., Hayden, P., Witte, T.J. de, Yakoub-Agha, I., Kröger, N., Forcade, E., Chevret, S., Finke, J., Ehninger, G., Ayuk, F., Beelen, D., Koster, L, Ganser, A., Volin, L., Sengeloev, H., Michallet, M., Tischer, J., Jindra, P., Cascon, M.J.P., Koc, Y., Arat, M., Tomaszewska, A., Hayden, P., Witte, T.J. de, Yakoub-Agha, I., and Kröger, N.

Abstract

Item does not contain fulltext, While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.

Published
2022

18. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party

Author

Scheid, C, de Wreede, L, van Biezen, A, Koenecke, C, Göhring, G, Volin, L, Maertens, J, Finke, J, Passweg, J, Beelen, D, Cornelissen, J J, Itälä-Remes, M, Chevallier, P, Russell, N, Petersen, E, Milpied, N, Espiga, C Richard, Peniket, A, Sierra, J, Mufti, G, Crawley, C, Veelken, J H, Ljungman, P, Cahn, J Y, Alessandrino, E P, de Witte, T, Robin, M, and Kröger, N

Published
2017
Full Text
View/download PDF

19. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author

Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, and Hasford, J

Published
2017
Full Text
View/download PDF

20. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Author

Zeiser, R, Burchert, A, Lengerke, C, Verbeek, M, Maas-Bauer, K, Metzelder, S K, Spoerl, S, Ditschkowski, M, Ecsedi, M, Sockel, K, Ayuk, F, Ajib, S, de Fontbrune, F S, Na, I-K, Penter, L, Holtick, U, Wolf, D, Schuler, E, Meyer, E, Apostolova, P, Bertz, H, Marks, R, Lübbert, M, Wäsch, R, Scheid, C, Stölzel, F, Ordemann, R, Bug, G, Kobbe, G, Negrin, R, Brune, M, Spyridonidis, A, Schmitt-Gräff, A, van der Velden, W, Huls, G, Mielke, S, Grigoleit, G U, Kuball, J, Flynn, R, Ihorst, G, Du, J, Blazar, B R, Arnold, R, Kröger, N, Passweg, J, Halter, J, Socié, G, Beelen, D, Peschel, C, Neubauer, A, Finke, J, Duyster, J, and von Bubnoff, N

Published
2015
Full Text
View/download PDF

24. Myelodysplastic Syndromes or Leukemia Following MDS Treated with Allogeneic Bone Marrow Transplantation: A Survey of the Working Party on Chronic Leukemia of the European Cooperative Group for Blood and Marrow Transplantation

Author

Runde, V., de Witte, T., Aul, C., Gratwohl, A., Niederwieser, D., van Biezen, A., Hermans, J., Vernant, J., Kolb, H., Vossen, J., Lönqvist, B., Beelen, D., Ferrant, A., Arnold, R., Cahn, J., van Lint, M., Verdonk, L., Apperley, J., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor

Published
1997
Full Text
View/download PDF

32. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

Author

Gratwohl, A, Pfirrmann, M, Zander, A, Kröger, N, Beelen, D, Novotny, J, Nerl, C, Scheid, C, Spiekermann, K, Mayer, J, Sayer, H G, Falge, C, Bunjes, D, Döhner, H, Ganser, A, Schmidt-Wolf, I, Schwerdtfeger, R, Baurmann, H, Kuse, R, Schmitz, N, Wehmeier, A, Th Fischer, J, Ho, A D, Wilhelm, M, Goebeler, M-E, Lindemann, H W, Bormann, M, Hertenstein, B, Schlimok, G, Baerlocher, G M, Aul, C, Pfreundschuh, M, Fabian, M, Staib, P, Edinger, M, Schatz, M, Fauser, A, Arnold, R, Kindler, T, Wulf, G, Rosselet, A, Hellmann, A, Schäfer, E, Prümmer, O, Schenk, M, Hasford, J, Heimpel, H, Hossfeld, D K, Kolb, H-J, Büsche, G, Haferlach, C, Schnittger, S, Müller, M C, Reiter, A, Berger, U, Sauele, S, Hochhaus, A, and Hehlmann, R

Published
2016
Full Text
View/download PDF

35. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (Bone Marrow Transplantation, (2020), 55, 6, (1114-1125), 10.1038/s41409-020-0803-y)

Author

Spyridonidis A., Labopin M., Savani B. N., Niittyvuopio R., Blaise D., Craddock C., Socie G., Platzbecker U., Beelen D., Milpied N., Cornelissen J. J., Ganser A., Huynh A., Griskevicius L., Giebel S., Aljurf M., Brissot E., Malard F., Esteve J., Peric Z., Baron F., Ruggeri A., Schmid C., Gilleece M., Gorin N. -C., Lanza F., Shouval R., Versluis J., Bug G., Floisand Y., Ciceri F., Sanz J., Bazarbachi A., Nagler A., Mohty M., Spyridonidis, A., Labopin, M., Savani, B. N., Niittyvuopio, R., Blaise, D., Craddock, C., Socie, G., Platzbecker, U., Beelen, D., Milpied, N., Cornelissen, J. J., Ganser, A., Huynh, A., Griskevicius, L., Giebel, S., Aljurf, M., Brissot, E., Malard, F., Esteve, J., Peric, Z., Baron, F., Ruggeri, A., Schmid, C., Gilleece, M., Gorin, N. -C., Lanza, F., Shouval, R., Versluis, J., Bug, G., Floisand, Y., Ciceri, F., Sanz, J., Bazarbachi, A., Nagler, A., and Mohty, M.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

40. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Author

Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, and Ottmann, O G

Published
2013
Full Text
View/download PDF

42. OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS

Author

Dreger, P., primary, Martus, P., additional, Holtick, U., additional, Ayuk, F., additional, Wagner‐Drouet, E. M., additional, Wulf, G., additional, Marks, R., additional, Penack, O., additional, Koenecke, C., additional, von Bonin, M., additional, von Tresckow, B., additional, Stelljes, M., additional, Baldus, C., additional, Vucinic, V., additional, Mougiakakos, D., additional, Topp, M., additional, Wolff, D., additional, Schroers, R., additional, Schmitt, M., additional, Schmitt, T., additional, Lengerke, C., additional, Thomas, S., additional, Beelen, D. W., additional, and Bethge, W., additional

Published
2021
Full Text
View/download PDF

43. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Author

Kröger, N., Sbianchi, G., Sirait, T., Wolschke, C., Beelen, D., Passweg, J., Robin, M., Vrhovac, R., Helbig, G., Sockel, K., Conneally, E., Rubio, M.T., Beguin, Y., Finke, J., Bernasconi, P., Morozova, E., Clausen, J., Borne, P. von dem, Schaap, N.P., Schroyens, W., Patriarca, F., Renzo, N. Di, Yeğin, Z.A., Hayden, P., McLornan, D., Yakoub-Agha, I., Kröger, N., Sbianchi, G., Sirait, T., Wolschke, C., Beelen, D., Passweg, J., Robin, M., Vrhovac, R., Helbig, G., Sockel, K., Conneally, E., Rubio, M.T., Beguin, Y., Finke, J., Bernasconi, P., Morozova, E., Clausen, J., Borne, P. von dem, Schaap, N.P., Schroyens, W., Patriarca, F., Renzo, N. Di, Yeğin, Z.A., Hayden, P., McLornan, D., and Yakoub-Agha, I.

Abstract

Item does not contain fulltext, JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.

Published
2021

44. Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

Author

Waidhauser, J., Labopin, M., Esteve, J., Kröger, N., Cornelissen, J, Gedde-Dahl, T., Gorkom, G. van, Finke, J., Rovira, M., Schaap, N.P., Petersen, Eefke, Beelen, D., Bunjes, D., Savani, B., Schmid, C., Nagler, A., Mohty, M., Waidhauser, J., Labopin, M., Esteve, J., Kröger, N., Cornelissen, J, Gedde-Dahl, T., Gorkom, G. van, Finke, J., Rovira, M., Schaap, N.P., Petersen, Eefke, Beelen, D., Bunjes, D., Savani, B., Schmid, C., Nagler, A., and Mohty, M.

Abstract

Contains fulltext : 243910.pdf (Publisher’s version ) (Open Access), Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1 mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and RUNX1 mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS/LFS), and GvHD-free/relapse-free survival. A total of 674 patients (183 RUNX1+, 491 RUNX1-) were identified, with >85% presenting as de novo AML. Median follow-up was 16.4 (RUNX1+) and 21.9 (RUNX1-) months. Survival rates showed no difference between RUNX1+ and RUNX1- patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%, p = 0.7; 2-year LFS: 61.1 vs. 60.8%, p = 0.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with RUNX+ AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of RUNX1 mutations in patients with AML can be overcome by transplantation in CR1.

Published
2021

45. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

Author

Shimoni, A., Robin, M., Iacobelli, S., Beelen, D., Mufti, G.J., Ciceri, F., Bethge, W., Volin, L., Blaise, D., Ganser, A., Luft, T., Chevallier, P., Schwerdtfeger, R., Koster, L, Witte, T.J. de, Kröger, N., Nagler, A., Yakoub-Agha, I., Shimoni, A., Robin, M., Iacobelli, S., Beelen, D., Mufti, G.J., Ciceri, F., Bethge, W., Volin, L., Blaise, D., Ganser, A., Luft, T., Chevallier, P., Schwerdtfeger, R., Koster, L, Witte, T.J. de, Kröger, N., Nagler, A., and Yakoub-Agha, I.

Abstract

Item does not contain fulltext, Allogeneic haematopoietic-cell transplantation (allo-HCT) is a potentially curative therapy for high-risk myelodysplastic syndrome (MDS). Reduced-intensity conditioning (RIC) is usually associated with lower non-relapse mortality (NRM), higher relapse rate and similar overall-survival (OS) as myeloablative-conditioning (MAC). Fludarabine/treosulfan (FT) is a reduced-toxicity regimen with intense anti-leukaemia activity and a favourable toxicity profile. We investigated post-transplant outcomes in 1722 MDS patients following allo-HCT with FT (n = 367), RIC (n = 687) or MAC (n = 668). FT and RIC recipients were older than MAC recipients, median age 59, 59 and 51 years, respectively (P < 0·001) but other disease characteristics were similar. The median follow-up was 64 months (1-171). Five-year relapse rates were 25% (21-30), 38% (34-42) and 25% (22-29), after FT, RIC and MAC, respectively, (P < 0·001). NRM was 30% (25-35), 27% (23-30) and 34% (31-38, P = 0·008), respectively. Five-year OS was 50% (44-55), 43% (38-47), and 43% (39-47), respectively (P = 0·03). In multivariate analysis, FT was associated with a lower risk of relapse (HR 0·55, P < 0·001) and better OS (HR 0·72, P = 0·01). MAC was associated with higher NRM (HR 1·44, P = 0·001). In conclusion, FT is associated with similar low relapse rates as MAC and similar low NRM as RIC, resulting in improved OS. FT may be the preferred regimen for allo-HCT in MDS.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results